These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 24521271)

  • 21. Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
    Casonato A; Pontara E; Morpurgo M; Sartorello F; De Groot PG; Cattini MG; Daidone V; De Marco L
    Br J Haematol; 2015 Dec; 171(5):845-53. PubMed ID: 26456374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How I treat type 2 variant forms of von Willebrand disease.
    Tosetto A; Castaman G
    Blood; 2015 Feb; 125(6):907-14. PubMed ID: 25477497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF.
    Yago T; Lou J; Wu T; Yang J; Miner JJ; Coburn L; López JA; Cruz MA; Dong JF; McIntire LV; McEver RP; Zhu C
    J Clin Invest; 2008 Sep; 118(9):3195-207. PubMed ID: 18725999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Type 2B and pseudo type 2B Von Willebrand disease; a report of three cases].
    Guermazi S; Conard J; Samama MM; Dellagi K
    Pathol Biol (Paris); 2006 Apr; 54(3):159-65. PubMed ID: 16176858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel platelet-type von Willebrand disease mutation (GP1BA p.Met255Ile) associated with type 2B "Malmö/New York" von Willebrand disease.
    Lavenu-Bombled C; Guitton C; Dupuis A; Baas MJ; Desconclois C; Dreyfus M; Li R; Caron C; Gachet C; Fressinaud E; Lanza F
    Thromb Haemost; 2016 Nov; 116(6):1070-1078. PubMed ID: 27683759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
    Doruelo AL; Haberichter SL; Christopherson PA; Boggio LN; Gupta S; Lentz SR; Shapiro AD; Montgomery RR; Flood VH
    J Thromb Haemost; 2017 Aug; 15(8):1559-1566. PubMed ID: 28544236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A family having type 2B von Willebrand disease with an R1306W mutation: Severe thrombocytopenia leads to the normalization of high molecular weight multimers.
    Ozeki M; Kunishima S; Kasahara K; Funato M; Teramoto T; Kaneko H; Fukao T; Kondo N
    Thromb Res; 2010 Feb; 125(2):e17-22. PubMed ID: 19740526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test.
    Michiels JJ; Smejkal P; Penka M; Batorova A; Pricangova T; Budde U; Vangenechten I; Gadisseur A
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):518-531. PubMed ID: 27443694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type 2B von Willebrand disease mutations differentially perturb autoinhibition of the A1 domain.
    Legan ER; Liu Y; Arce NA; Parker ET; Lollar P; Zhang XF; Li R
    Blood; 2023 Mar; 141(10):1221-1232. PubMed ID: 36580664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease.
    Ay C; Pabinger I; Kovacevic KD; Gelbenegger G; Schörgenhofer C; Quehenberger P; Jilma-Stohlawetz P; Sunder-Plassman R; Gilbert JC; Zhu S; Jilma B; Derhaschnig U
    Blood Adv; 2022 Sep; 6(18):5467-5476. PubMed ID: 35772170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of inherited von Willebrand disease in 2007.
    Federici AB; Mannucci PM
    Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
    Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C
    Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease.
    Chegeni R; Vickars L; Favaloro EJ; Lillicrap D; Othman M
    Thromb Res; 2011 Feb; 127(2):161-6. PubMed ID: 21094983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip-based flow chamber system.
    Ogiwara K; Nogami K; Hosokawa K; Ohnishi T; Matsumoto T; Shima M
    Haemophilia; 2015 Jan; 21(1):71-80. PubMed ID: 25545301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?
    Favaloro EJ
    Semin Thromb Hemost; 2008 Feb; 34(1):113-27. PubMed ID: 18393148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced Local Disorder in a Clinically Elusive von Willebrand Factor Provokes High-Affinity Platelet Clumping.
    Tischer A; Machha VR; Frontroth JP; Brehm MA; Obser T; Schneppenheim R; Mayne L; Walter Englander S; Auton M
    J Mol Biol; 2017 Jul; 429(14):2161-2177. PubMed ID: 28533135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.
    Tischer A; Brehm MA; Machha VR; Moon-Tasson L; Benson LM; Nelton KJ; Leger RR; Obser T; Martinez-Vargas M; Whitten ST; Chen D; Pruthi RK; Bergen HR; Cruz MA; Schneppenheim R; Auton M
    J Mol Biol; 2020 Jan; 432(2):305-323. PubMed ID: 31628947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
    Castaman G; Tosetto A; Federici AB; Rodeghiero F
    Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder.
    Othman M
    Semin Thromb Hemost; 2011 Jul; 37(5):464-9. PubMed ID: 22102188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.